Overcoming barriers for global CGT adoption
![DNA Molecular Genetic Science Biotechnology](/sites/default/files/styles/x_large/public/2025-01/DNA-Molecular-Genetic-Science-Biotechnology.jpg?itok=kN6MDbai)
Cell and gene therapies (CGT) have emerged as the next big thing in medicine, holding the power to deliver cures where none previously existed. Cell therapy typically involves modifying or engineering cells outside the body to fight diseases when reintroduced, while gene therapy uses genetic engineering to replace, remove, or repair defective genes within a patient's cells.
By 2025, these therapies are poised to become game-changers globally projected to hit around $52.40 billion by 2033, giving patients access to life-altering treatments and reshaping healthcare and the life sciences industry as we know it. However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and logistical challenges to fragmented regulatory systems and patient awareness gaps.
Balancing innovation with accessibility
At the core of CGT’s global expansion lies a critical issue - scalability. Manufacturing these therapies is resource intensive, requiring state-of-the-art facilities and processes that come with hefty price tags. For biotech companies looking to expand into emerging markets, the financial burden can prohibit success. Automation offers a solution by improving efficiency, reducing errors, and driving consistency in production. Yet, the high cost of adopting advanced technologies often shuts smaller biotech players and underserved regions out of the game.
To make CGT accessible worldwide, the industry must focus on scalable, cost-effective solutions. This includes innovating modular manufacturing systems, establishing shared production facilities, and leveraging public-private partnerships to reduce financial risk. Collaboration with local players in emerging markets can also help distribute the cost burden while fostering regional expertise and infrastructure.
Navigating logistical barriers
Delivering CGT to patients adds another layer of complexity. These therapies are time-sensitive, requiring strict temperature controls and seamless logistics throughout the supply chain. Delays or failures at any point in the process – whether due to infrastructure gaps, environmental disruptions, or inadequate regional support systems – can jeopardise the treatment’s viability.
Emerging markets face the greatest risks here. Many regions still lack the infrastructure needed to support advanced supply chains, particularly for therapies that require cold-chain logistics. Environmental factors, such as extreme weather events or natural disasters, further compound the challenge, creating unpredictability that hinders timely delivery.To address these issues, biotech companies must invest in resilient, technology-driven logistics systems. Advanced cold-chain solutions, real-time tracking powered by IoT devices, and predictive analytics for risk management can help ensure reliability, even in challenging environments. Additionally, partnering with local logistics providers and stakeholders will be essential for building trust and creating robust delivery networks that can adapt to regional conditions. The goal is clear: every patient, regardless of location, must be able to access CGT safely and on time.
Regulatory harmonisation and streamlining approvals
While many are eager to embrace CGT, the lack of harmonised regulations creates bottlenecks. Inconsistent clinical trial requirements, approval processes, and safety standards add delays and costs, slowing down CGT’s global adoption. Countries vary widely in their clinical trial requirements, approval pathways, and safety standards, creating inefficiencies that slow down the development and rollout of these therapies. For companies working across multiple regions, navigating this patchwork of regulations can be time-consuming, expensive, and resource-draining.
The lack of regulatory harmonisation also risks creating a two-tiered system, where patients in regions with streamlined processes gain access to CGT far sooner than those in less developed markets. To address this disparity, industry leaders must work together with global regulatory agencies, policymakers, and patient advocacy groups to create consistent, evidence-based standards that transcend borders.
Programs like the FDA’s Gene Therapy Pilot initiative offer a promising model, providing developers with early feedback and guidance to de-risk pathways and streamline approvals. Expanding these collaborative frameworks on an international scale could accelerate the process of bringing CGT to market while maintaining the highest standards of safety and efficacy. Harmonised regulations will not only improve efficiency, but also ensure that patients everywhere can benefit from these groundbreaking therapies at the same pace.
Educating patients and building trust
As CGT gains prestige, patient awareness remains uneven. Misleading claims and misinformation have complicated trust, creating confusion and scepticism among patients who might otherwise benefit from legitimate therapies. To combat this, biotech companies must prioritise education and transparency. Proactive campaigns that demystify CGT, explain its benefits, and highlight safety standards can empower patients to make informed decisions. Collaboration with healthcare providers, patient advocacy groups, and regulators will ensure that accurate information reaches the communities that need it most.
Turning barriers into breakthroughs
By tackling the financial, logistical, and regulatory challenges head-on, the biotech industry can ensure that these transformative therapies reach every corner of the globe. Cutting-edge science must be met with practical solutions – scalable production systems, strengthened supply chains, harmonised regulatory processes, and widespread education initiatives.
CGT represents more than medical innovation: it is a chance to redefine healthcare for the future. To make this vision a reality, the industry must act with urgency, collaboration, and a commitment to equity. The patients waiting for these therapies deserve nothing less.
By addressing these challenges head-on – cutting costs, streamlining logistics, harmonising regulations, and building trust – the biotech industry can turn today’s barriers into tomorrow’s breakthroughs. The future of healthcare depends on making CGT a reality for patients everywhere, not just for a privileged few.